Melatonin (MT), a hormone secreted from the pineal gland, has beneficial effects on the development of diabetic nephropathy (DN). In our study, we aimed to determine the effects of melatonin on renal inflammation and fibrosis in diabetic nephropathy. , we evaluated the blood and urine indices of metabolic and renal function, renal inflammation and renal fibrosis in db/db mice after melatonin treatment. Melatonin treatment significantly decreased urinary albumin excretion and reduced the morphological changes in kidney. Additionally, Melatonin reduced the levels of inflammatory factors in kidney such as interleukin-1β, monocyte chemotactic protein-1 and active nuclear factor-κB though toll-like receptor 4 signaling pathway (TLR4). Melatonin also reduced collagen type IV, fibronectin, transforming growth factor-β1 (TGF-β1) and decreased the phosphorylation of Smad3 in the renal tissue. These results indicated that melatonin reduced the inflammation and fibrosis in diabetic nephropathy though TLR4 and TGF-β1/Smad3 signaling pathway. , melatonin treatment reduced the cell proliferation, inflammatory factors releasing, TLR4 and TGF-β1/Smad3 signaling pathway. Our findings indicated that melatonin may provide a new perspective intervention to halt the hyperglycemia-induced inflammatory response of DN.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270025 | PMC |
J Cell Mol Med
March 2025
Department of Cardiology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Recent research has revealed a close association between obesity and various metabolic disorders, including renal metabolic diseases, but the mechanism is still unknown. This study explored the role of p16INK4a in obesity-related kidney fibrosis and evaluated its potential as a therapeutic target. Using wild-type (WT) mice and p16 KO mice, we fed both groups a high-fat diet (HFD) for 6 months.
View Article and Find Full Text PDFCurr Med Res Opin
March 2025
Division of Rheumatology, Allergy and Immunology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Background: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder that significantly impacts renal function. Despite conventional treatments, morbidity and mortality remain high, necessitating the exploration of safer and more effective therapies, including the potential benefits of Traditional Chinese Medicine (TCM) for improving kidney health and survival rates.
Methods: Patients with newly diagnosed with SLE with catastrophic illness certificate were retrospectively enrolled from CGRD between 2005 and 2020.
R Soc Open Sci
March 2025
Interface Analysis Centre, HH Wills Physics Laboratory, School of Physics, University of Bristol, Bristol, UK.
Transplantation is the standard treatment for end-stage kidney disease but carries with it a non-trivial risk of post-operative complication. There is a need for a continuous, real-time, not additionally invasive method of monitoring organ perfusion. We present an approach to allograft perfusion monitoring using a human kidney model using normothermic perfusion (EVNP) and custom spectroscopic optical reflectance probes.
View Article and Find Full Text PDFCan J Kidney Health Dis
March 2025
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, AB, Canada.
Purpose Of The Review: Immunoglobulin A (IgA) nephropathy (IgAN) is the most common primary glomerular kidney disease. Children and adults are presumed to have the same disease and are treated similarly. However, there are differences between childhood IgAN and adult IgAN that may require unique treatment considerations, even after transition to adult nephrology services.
View Article and Find Full Text PDFExpert Opin Biol Ther
March 2025
Servicio de Reumatología. Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain.
Introduction: Belimumab (BEL), an anti B-lymphocyte stimulator monoclonal antibody, is the only approved biological therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN).
Areas Covered: This review discusses BEL's real-world use and its positioning in clinical practice guidelines, focusing on the evolution of its application and patient profile over the last decade in Spain.
Expert Opinion: Initially used for refractory, non-major SLE manifestations, BEL's application has expanded.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!